Showing 1 - 3 results of 3 for search 'EMPRISE East Asia Study Group', query time: 0.02s Refine Results
  1. 1
    Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study

    Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study by Dae Jung Kim, Wayne H‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino, EMPRISE East Asia Study Group

    Published 2023-03-01
    Get full text
    Article
  2. 2
    Healthcare resource utilization in patients treated with empagliflozin in East Asia

    Healthcare resource utilization in patients treated with empagliflozin in East Asia by Wayne H‐H Sheu, Yutaka Seino, Elise Chia‐Hui Tan, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Wook‐Jin Chung, Koichi Node, Atsutaka Yasui, Wei‐Yu Lei, Sunwoo Lee, Anastasia Ustyugova, Riho Klement, Anouk Deruaz‐Luyet, Moe H Kyaw, Dae Jung Kim, the EMPRISE East Asia study group

    Published 2022-05-01
    Get full text
    Article
  3. 3
    Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study

    Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study by Yutaka Seino, Dae Jung Kim, Daisuke Yabe, Elise Chia‐Hui Tan, Wook‐Jin Chung, Kyoung Hwa Ha, Masaomi Nangaku, Koichi Node, Riho Klement, Atsutaka Yasui, Wei‐Yu Lei, Sunwoo Lee, Moe H. Kyaw, Anouk Deruaz‐Luyet, Kimberly G. Brodovicz, Wayne H.‐H. Sheu, the EMPRISE East Asia study group

    Published 2021-01-01
    Get full text
    Article

Search Tools: